Corrected: Lilly upped its offer for Morphic by $11 per share, documents show
Industry insiders love to say biotechs are bought, not sold. That appears to be the case with autoimmune drug developer Morphic Therapeutic, which is trying to create a next-generation, oral medicine...
View Article#ASRS24: Roivant recently sold one spinout for billions. Is Priovant next?
When Roivant announced positive Phase 2 data of a key inflammatory drug back in April, the CEO of Priovant — the subsidiary in charge of development — started to get more calls. The drug, brepocitinib,...
View ArticleOrbiMed forms biotech with assets from China-based Keymed, enlists former...
OrbiMed, a longtime biotech funder, created a startup with two bispecific antibodies licensed from a drugmaker in China and put a former Biohaven executive at the helm. Belenos Biosciences, a New...
View ArticleRona Therapeutics raises $35M; Actuate now plans for $22M IPO
Shanghai-based RNA company raises $35 million: Rona Therapeutics’ Series A+ round was led by LongRiver Investments. Investors include Lilly Asia Ventures, among others. The company is developing RNA...
View ArticleEuropean Commission president’s second-term pledge: simpler regulations,...
Ursula von der Leyen won a second term as president of the European Commission on Thursday, with 401 votes in favor from a total of 719 in the European Parliament. After her win, von der Leyen...
View ArticleUS inks $113M deal with Siga to bolster smallpox, mpox reserves
The US government is paying Siga $113 million to stockpile additional courses of the smallpox and mpox treatment known as Tpoxx. The project falls under the government’s strategic preparedness plan and...
View ArticleEMA reasserts differences with FDA for Covid vaccine strain selection
The European Medicines Agency (EMA) on Friday reconfirmed that its strain selection for Covid-19 vaccines for the fall season will differ slightly from the FDA’s selection, pending any further...
View ArticleVermont attorney general sues two major PBMs for allegedly driving up costs
The deluge of legal action against pharmacy benefit managers continued Wednesday, with Vermont Attorney General Charity Clark filing a lawsuit claiming that PBMs are behind an illegal effort to drive...
View ArticleChina approves Eli Lilly's weight loss drug as country launches obesity...
Eli Lilly’s tirzepatide has been approved for weight management in China, entering what’s expected to be a substantial market for GLP-1s. Tirzepatide — marketed in the US as Mounjaro for diabetes and...
View ArticleA rare disease first; Lilly’s Alzheimer’s push; Argenx’s next act; Novartis'...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleChinese biotech Gan & Lee boasts competitive Phase 2b weight loss data for...
Fresh off Eli Lilly’s tirzepatide approval for weight loss in China, Beijing-based Gan & Lee Pharmaceuticals posted Phase 2b data of its GLP-1 rival that stacks up positively against market...
View ArticleClik here to view.
HI-Bio dishes on motivations for Biogen buyout, citing desire to move fast
Why did Human Immunology Biosciences get bought out less than five months after closing a $95 million Series B? HI-Bio’s executives were highly confident in the company’s lead program, felzartamab, and...
View ArticleClik here to view.
Agilent Technologies to acquire CDMO Biovectra for $925M
Agilent Technologies plans to buy Canadian CDMO Biovectra in a $925 million deal, which Agilent says will deepen its focus on oligonucleotides and CRISPR. Biovectra says it has fill-finish services,...
View ArticleSino Biopharm's invoX to restructure, likely cutting about 60 roles
Oncology and respiratory drug developer invoX Pharma is fine-tuning its pipeline and expects to cut about one-third of its employees, the company confirmed to Endpoints News. London-based invoX has...
View ArticleNorth Carolina's Medicaid program to cover weight loss drugs beginning in August
North Carolina will join the list of several states that have started covering obesity drugs, citing the positive effect they can have not just on weight, but with the comorbidities that often...
View ArticleUpdated: Samsung wins FDA approval for second Soliris biosimilar
Samsung Bioepis said Monday that the FDA approved its biosimilar to AstraZeneca’s blockbuster immunosuppressive drug Soliris. And now the company is saying that the approval, for two types of rare...
View ArticleBluebird bio handed negative opinion from federal oversight agency for...
HHS’ Office of the Inspector General has issued a negative advisory opinion for a fertility support program proposed by bluebird bio, less than a week after Vertex sued the federal government over...
View ArticleWuXi AppTec more than tripled lobbying spend as Biosecure Act advanced in...
China’s WuXi AppTec spent at least $360,000 lobbying on the Biosecure Act and other bills before Congress in the second quarter, significantly upping its lobbying work as the company pushed back...
View ArticleWhere Oak HC/FT investor Nancy Brown is placing her bets on AI in health tech
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Nancy Brown used to wear a t-shirt that featured a shiny object and the word “no.” It’s the rule she...
View ArticleClik here to view.
Health tech startup Commure bets on AI for medical notes in $139M deal
Health tech startup Commure said Friday that it has agreed to buy AI medical scribe company Augmedix for $139 million to beef up its software tools for health systems and doctors. The deal, which will...
View Article